Literature DB >> 24531557

Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warning.

Anchalee Avihingsanon1, Reshmie A Ramautarsing2, Gompol Suwanpimolkul3, Ploenchan Chetchotisakd4, Chureeratana Bowonwatanuwong5, Supunnee Jirajariyavej6, Patcharee Kantipong7, Hutsaya Tantipong5, June Pirapon Ohata8, Chusana Suankratay3, Kiat Ruxrungtham2, David M Burger9.   

Abstract

Ergotism is a toxic condition resulting from overexposure to the ergot compounds produced by various fungi of the genus Claviceps. Traditionally, such exposure was due to ingestion of infected grains, but long-term or excessive use of medications containing ergot derivatives or drug-drug interactions between these medications can result in ergotism. Ergotamine, typically used to treat migraine, has less than 5% bioavailability due to extensive first-pass metabolism by cytochrome P450 3A4 (CYP3A4). Concurrent intake of ergotamine and strong CYP3A4 inhibitors, such as the HIV protease inhibitors (PIs), can lead to clinical ergotism. A total of 13 cases of clinical ergotism in HIV-infected patients has been published since 1997 (most recently reviewed by Frohlich et al).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531557      PMCID: PMC6148849     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  3 in total

1.  Holy fire in an HIV-positive man: a case of 21st-century ergotism.

Authors:  Georg Fröhlich; Vladimir Kaplan; Beatrice Amann-Vesti
Journal:  CMAJ       Date:  2010-01-04       Impact factor: 8.262

2.  iAIDS: HIV-related internet resources for the practicing clinician.

Authors:  Douglas Krakower; Candice K Kwan; David S Yassa; Richard A Colvin
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

Review 3.  The pharmacology of ergotamine and dihydroergotamine.

Authors:  S D Silberstein
Journal:  Headache       Date:  1997       Impact factor: 5.887

  3 in total
  3 in total

Review 1.  Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.

Authors:  Yuqing Gong; Sanjana Haque; Pallabita Chowdhury; Theodore J Cory; Sunitha Kodidela; Murali M Yallapu; John M Norwood; Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-04-20       Impact factor: 4.481

Review 2.  The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

Authors:  Alice Tseng; Jason Seet; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 3.  Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.

Authors:  Karen J Tulloch; Philippe Dodin; Fannie Tremblay-Racine; Chelsea Elwood; Deborah Money; Isabelle Boucoiran
Journal:  J Int AIDS Soc       Date:  2019-06       Impact factor: 5.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.